Back to top
more

BioRad Laboratories (BIO)

(Real Time Quote from BATS)

$263.27 USD

263.27
117,625

-8.91 (-3.27%)

Updated Aug 6, 2025 12:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.

Zacks Equity Research

Catalent's (CTLT) Q4 Earnings Top Estimates, Margins Rise

by Zacks Equity Research

Catalent's (CTLT) robust performance across the majority of its segments drives its fourth-quarter fiscal 2021 top line.

Zacks Equity Research

Cooper Companies (COO) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Cooper Companies' (COO) fiscal third-quarter results are likely to reflect segmental strength.

Zacks Equity Research

Zacks.com featured highlights include: NBT Bancorp, Bio-Rad Laboratories, RadNet, Arbor Realty Trust and Cathay General Bancorp

by Zacks Equity Research

Zacks.com featured highlights include: NBT Bancorp, Bio-Rad Laboratories, RadNet, Arbor Realty Trust and Cathay General Bancorp

Shrabana Mukherjee headshot

New Analyst Coverage Puts Spotlight on These 5 Stocks

by Shrabana Mukherjee

Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like NBTB, BIO, RDNT, ABR and CATY.

Zacks Equity Research

What's in Store for Patterson Companies' (PDCO) Q1 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect improvement at Dental segment.

Zacks Equity Research

Medtronic's (MDT) Q1 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Medtronic's (MDT) fiscal first-quarter results reflect a strong recovery from the impact of the COVID-19 pandemic on elective procedures that the company experienced in 2020.

Zacks Equity Research

Zacks.com featured highlights include: Veritiv Corp, Lifetime Brands, Grindrod Shipping, Costamare and Bio-Rad Lab

by Zacks Equity Research

Zacks.com featured highlights include: Veritiv Corp, Lifetime Brands, Grindrod Shipping, Costamare and Bio-Rad Lab

Nalak Das headshot

5 Stocks With Recent Price Strength Amid Robust Reopening

by Nalak Das

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength like VRTV, LCUT, GRIN, CMRE and BIO have a high chance of carrying the momentum forward.

Zacks Equity Research

Alcon (ALC) Q2 Earnings Top Estimates, 2021 Guidance Up

by Zacks Equity Research

Alcon (ALC) records the highest sales in the second quarter of 2021 since its spin-off.

Zacks Equity Research

Bio-Rad (BIO) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Strong performance across the Life Science and Clinical Diagnostics businesses drove the top line for Bio-Rad (BIO).

Zacks Equity Research

Omnicell (OMCL) Rides on New Buyout, Innovation Amid Pandemic

by Zacks Equity Research

Omnicell (OMCL) accelerates shift to cloud-based solutions and tech-enabled services through the launches of Omnicell One and Central Pharmacy Dispensing Services.

Zacks Equity Research

Zacks.com featured highlights include: Cathay General Bancorp, Bio-Rad Laboratories, Chemed Corp, Materialise and Arbor Realty Trust

by Zacks Equity Research

Zacks.com featured highlights include: Cathay General Bancorp, Bio-Rad Laboratories, Chemed Corp, Materialise and Arbor Realty Trust

Shrabana Mukherjee headshot

5 Stocks to Buy as Analysts Initiate Coverage

by Shrabana Mukherjee

Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like CATY, BIO, CHE, MTLS and ABR.

Zacks Equity Research

Accuray (ARAY) Posts In-Line Q4 Earnings, Beats on Revenues

by Zacks Equity Research

Accuray (ARAY) registers growth in Service and Product revenues during fiscal Q4.

Zacks Equity Research

Here's Why You Should Add Chemed (CHE) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about Chemed (CHE) on strong segmental growth and raised Roto-Rooter and earnings guidance for 2021.

Zacks Equity Research

Surging Earnings Estimates Signal Upside for Bio-Rad (BIO) Stock

by Zacks Equity Research

Bio-Rad (BIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Inari Medical (NARI) Q2 Earnings Lag, Revenues Top Estimates

by Zacks Equity Research

Inari Medical's (NARI) second-quarter 2021 results benefit from significant revenue growth and gross margin expansion.

Zacks Equity Research

ShockWave Medical (SWAV) Q2 Earnings, Revenues Top Estimates

by Zacks Equity Research

ShockWave Medical's (SWAV) robust performance across product lines and geographies drive its Q2 sales.

Zacks Equity Research

Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO) backed by strong segmental performance across geographies in the second quarter and raised 2021 guidance.

Zacks Equity Research

Allscripts' (MDRX) Shares Up Following Q2 Earnings Beat

by Zacks Equity Research

Allscripts' (MDRX) robust Q2 results demonstrate its strength in Client services segment.

Zacks Equity Research

Glaukos (GKOS) Stock Gains 0.1% Following Lower Loss in Q2

by Zacks Equity Research

Despite reporting second-quarter loss, Glaukos' (GKOS) results reflect a significant rise in revenues.

Zacks Equity Research

What Makes Bio-Rad (BIO) a Good Fit for "Trend Investing"

by Zacks Equity Research

Bio-Rad (BIO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Equity Research

AMN Healthcare (AMN) Q2 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

AMN Healthcare's (AMN) robust Q2 results demonstrate its segmental strength.

Zacks Equity Research

Nevro (NVRO) Q2 Earnings Surpass Estimates, Revenues Lag

by Zacks Equity Research

Nevro's (NVRO) worldwide revenues rise on a year-over-year basis in Q2 despite pandemic-led business challenges.

Zacks Equity Research

Quidel (QDEL) Q2 Earnings Fall Shy of Estimates, Margins Down

by Zacks Equity Research

Quidel's (QDEL) dismal Q2 performance stems from lower revenues across majority of its product categories.